Bayer with continued strong performance
08
November
2022
|
07:30 AM
Europe/Amsterdam
Third quarter of 2022
Summary
Crew sales elevate by 5.7 p.c (Fx & portfolio adj.) to 11.281 billion euros / EBITDA sooner than special items rises by 17.3 p.c to 2.451 billion euros / Prick Science achieves sturdy sales good points – sales also up at Prescription medication and User Successfully being / All divisions file important elevate in earnings / Core earnings per part climb by 7.6 p.c to 1.13 euros / To find earnings at 546 million euros / Free cash circulation at 1.738 billion euros / Essential progress in Prescription medication pipeline / Fat-year Crew outlook confirmed
